

# HB0110S01 compared with HB0110

{deleted text} shows text that was in HB0110 but was deleted in HB0110S01.

Inserted text shows text that was not in HB0110 but was inserted into HB0110S01.

**DISCLAIMER:** This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

Representative Paul Ray proposes the following substitute bill:

## CONTROLLED SUBSTANCE AMENDMENTS

2017 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Paul Ray**

Senate Sponsor: \_\_\_\_\_

Cosponsor:

Carol Spackman Moss

---

---

### LONG TITLE

#### General Description:

This bill modifies the Utah Controlled Substances Act {regarding Schedule I}.

#### Highlighted Provisions:

This bill:

- ▶ adds the {substance} following to the list of controlled substances under Schedule I:
  - 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide {that is} <sub>2</sub>  
also known as U-47700 or "pink" {to the list of} <sub>2</sub>
  - Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
  - Butyryl fentanyl: N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide;
  - Furanyl fentanyl: and

## HB0110S01 compared with HB0110

N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide; and

- ▶ adds the following to listed controlled substances ~~{ under Schedule I }~~:
- ADB-CHMINACA: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide;
  - ADB-FUBINACA: (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide); and
  - FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate.

### Money Appropriated in this Bill:

None

### Other Special Clauses:

This bill provides a special effective date.

### Utah Code Sections Affected:

AMENDS:

**58-37-4**, as last amended by Laws of Utah 2015, Chapter 258

**58-37-4.2**, as last amended by Laws of Utah 2014, Chapter 23

---

---

*Be it enacted by the Legislature of the state of Utah:*

Section 1. Section **58-37-4** is amended to read:

**58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.**

(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

(i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) Acetyl-alpha-methylfentanyl

(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

## HB0110S01 compared with HB0110

~~[(B)]~~ [(B)] Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

~~[(B)]~~ [(C)] Acetylmethadol;

~~[(C)]~~ [(D)] Allylprodine;

~~[(D)]~~ [(E)] Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

~~[(E)]~~ [(F)] Alphameprodine;

~~[(F)]~~ [(G)] Alphamethadol;

~~[(G)]~~ [(H)] Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

~~[(H)]~~ [(I)] Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

~~[(I)]~~ [(J)] Benzylpiperazine;

~~[(J)]~~ [(K)] Benzethidine;

~~[(K)]~~ [(L)] Betacetylmethadol;

~~[(L)]~~ [(M)] Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

~~[(M)]~~ [(N)] Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;

~~[(N)]~~ [(O)] Betameprodine;

~~[(O)]~~ [(P)] Betamethadol;

~~[(P)]~~ [(Q)] Betaprodine;

[(R)] Butyryl fentanyl: N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide;

~~[(R)]~~ [(S)] Clonitazene;

~~[(S)]~~ [(T)] Dextromoramide;

~~[(T)]~~ [(U)] Diampromide;

~~[(U)]~~ [(V)] Diethylthiambutene;

~~[(V)]~~ [(W)] Difenoxyin;

~~[(W)]~~ [(X)] Dimenoxadol;

~~[(X)]~~ [(Y)] Dimepheptanol;

~~[(Y)]~~ [(Z)] Dimethylthiambutene;

~~[(Z)]~~ [(AA)] Dioxaphetyl butyrate;

## HB0110S01 compared with HB0110

~~[(Z)]~~ [(BB)] Dipipanone;

~~[(AA)]~~ [(CC)] Ethylmethylthiambutene;

~~[(BB)]~~ [(DD)] Etonitazene;

~~[(CC)]~~ [(EE)] Etoperidone;

[(FF)] Furanyl fentanyl: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]

### furan-2-carboxamide

~~[(DD)]~~ [(GG)] Furethidine;

~~[(EE)]~~ [(HH)] Hydroxypethidine;

~~[(FF)]~~ [(II)] Ketobemidone;

~~[(GG)]~~ [(JJ)] Levomoramide;

~~[(HH)]~~ [(KK)] Levophenacymorphan;

~~[(H)]~~ [(LL)] Morpheridine;

~~[(J)]~~ [(MM)] MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

~~[(K)]~~ [(NN)] Noracymethadol;

~~[(L)]~~ [(OO)] Norlevorphanol;

~~[(M)]~~ [(PP)] Normethadone;

~~[(N)]~~ [(QQ)] Norpipanone;

~~[(O)]~~ [(RR)] Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide;

~~[(P)]~~ [(SS)] PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);

~~[(Q)]~~ [(TT)] Phenadoxone;

~~[(R)]~~ [(UU)] Phenampromide;

~~[(S)]~~ [(VV)] Phenomorphan;

~~[(T)]~~ [(WW)] Phenoperidine;

~~[(U)]~~ [(XX)] Piritramide;

~~[(V)]~~ [(YY)] Proheptazine;

~~[(W)]~~ [(ZZ)] Properidine;

~~[(X)]~~ [(AAA)] Propiram;

~~[(Y)]~~ [(BBB)] Racemoramide;

~~[(Z)]~~ [(CCC)] Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide;

## HB0110S01 compared with HB0110

~~[(AAA)]~~ [(DDD)] Tilidine;

~~[(BBB)]~~ [(EEE)] Trimeperidine;

~~[(CCC)]~~ [(FFF)] 3-methylfentanyl, including the optical and geometric isomers (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide); ~~[and]~~

~~[(DDD)]~~ [(GGG)] 3-methylthiofentanyl

(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)[-]; and

~~[(EEE)]~~ [(HHH)] 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also known as U-47700.

(ii) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (A) Acetorphine;
- (B) Acetyldihydrocodeine;
- (C) Benzylmorphine;
- (D) Codeine methylbromide;
- (E) Codeine-N-Oxide;
- (F) Cyprenorphine;
- (G) Desomorphine;
- (H) Dihydromorphine;
- (I) Drotebanol;
- (J) Etorphine (except hydrochloride salt);
- (K) Heroin;
- (L) Hydromorphanol;
- (M) Methyldesorphine;
- (N) Methylhydromorphine;
- (O) Morphine methylbromide;
- (P) Morphine methylsulfonate;
- (Q) Morphine-N-Oxide;
- (R) Myrophine;
- (S) Nicocodeine;
- (T) Nicomorphine;

## HB0110S01 compared with HB0110

- (U) Normorphine;
- (V) Pholcodine; and
- (W) Thebacon.

(iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position, and geometric isomers:

- (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;  $\alpha$ -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;  $\alpha$ -ET; and AET;
- (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 4-bromo-2,5-dimethoxy- $\alpha$ -methylphenethylamine; 4-bromo-2,5-DMA;
- (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
- (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- $\alpha$ -methylphenethylamine; 2,5-DMA;
- (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
- (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- $\alpha$ -methylphenethylamine; paramethoxyamphetamine, PMA;
- (G) 5-methoxy-3,4-methylenedioxyamphetamine;
- (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5-dimethoxy- $\alpha$ -methylphenethylamine; "DOM"; and "STP";
- (I) 3,4-methylenedioxy amphetamine;
- (J) 3,4-methylenedioxymethamphetamine (MDMA);
- (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
- (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
- (M) 3,4,5-trimethoxy amphetamine;
- (N) Bufotenine, some trade and other names:

## HB0110S01 compared with HB0110

3-( $\beta$ -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;

(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;

(P) Dimethyltryptamine, some trade or other names: DMT;

(Q) Ibogaine, some trade and other names:

7-Ethyl-6,6 $\beta$ ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga;

(R) Lysergic acid diethylamide;

(S) Marijuana;

(T) Mescaline;

(U) Parahexyl, some trade or other names:

3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;

(V) Peyote, meaning all parts of the plant presently classified botanically as *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));

(W) N-ethyl-3-piperidyl benzilate;

(X) N-methyl-3-piperidyl benzilate;

(Y) Psilocybin;

(Z) Psilocyn;

(AA) Tetrahydrocannabinols, naturally contained in a plant of the genus *Cannabis* (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of *Cannabis*, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:  $\Delta$ 1 cis or trans tetrahydrocannabinol, and their optical isomers  $\Delta$ 6 cis or trans tetrahydrocannabinol, and their optical isomers  $\Delta$ 3,4 cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered;

(BB) Ethylamine analog of phencyclidine, some trade or other names:

N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,

## HB0110S01 compared with HB0110

N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

(CC) Pyrrolidine analog of phencyclidine, some trade or other names:

1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

(DD) Thiophene analog of phencyclidine, some trade or other names:

1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and

(EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

(iv) Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(A) Mecloqualone; and

(B) Methaqualone.

(v) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers:

(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine;

(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;

(C) Fenethylamine;

(D) Methcathinone, some other names: 2-(methylamino)-propionophenone; alpha-(methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropionophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of optical isomers;

(E) ( $\pm$ )cis-4-methylaminorex (( $\pm$ )cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

(F) N-ethylamphetamine; and

(G) N,N-dimethylamphetamine, also known as

N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.

(vi) Any material, compound, mixture, or preparation which contains any quantity of



## HB0110S01 compared with HB0110

the following substances, including their optical isomers, salts, and salts of isomers, subject to temporary emergency scheduling:

- (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
- (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).

(vii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.

(b) Schedule II:

(i) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including:

- (I) Raw opium;
- (II) Opium extracts;
- (III) Opium fluid;
- (IV) Powdered opium;
- (V) Granulated opium;
- (VI) Tincture of opium;
- (VII) Codeine;
- (VIII) Ethylmorphine;
- (IX) Etorphine hydrochloride;
- (X) Hydrocodone;
- (XI) Hydromorphone;
- (XII) Metopon;
- (XIII) Morphine;
- (XIV) Oxycodone;
- (XV) Oxymorphone; and
- (XVI) Thebaine;

## HB0110S01 compared with HB0110

(B) Any salt, compound, derivative, or preparation which is chemically equivalent or identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these substances may not include the isoquinoline alkaloids of opium;

(C) Opium poppy and poppy straw;

(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation which is chemically equivalent or identical with any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, whether derived from the coca plant or synthetically produced, except the substances may not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and

(E) Concentrate of poppy straw, which means the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.

(ii) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation, except dextrophan and levopropoxyphene:

(A) Alfentanil;

(B) Alphaprodine;

(C) Anileridine;

(D) Bezitramide;

(E) Bulk dextropropoxyphene (nondosage forms);

(F) Carfentanil;

(G) Dihydrocodeine;

(H) Diphenoxylate;

(I) Fentanyl;

(J) Isomethadone;

(K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

(L) Levomethorphan;

(M) Levorphanol;

(N) Metazocine;

## HB0110S01 compared with HB0110

- (O) Methadone;
- (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
- (R) Pethidine (meperidine);
- (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- (V) Phenazocine;
- (W) Piminodine;
- (X) Racemethorphan;
- (Y) Racemorphan;
- (Z) Remifentanil; and
- (AA) Sufentanil.

(iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

- (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- (B) Methamphetamine, its salts, isomers, and salts of its isomers;
- (C) Phenmetrazine and its salts; and
- (D) Methylphenidate.

(iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (A) Amobarbital;
- (B) Glutethimide;
- (C) Pentobarbital;
- (D) Phencyclidine;
- (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and

## HB0110S01 compared with HB0110

1-piperidinocyclohexanecarbonitrile (PCC); and

(F) Secobarbital.

(v) (A) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of Phenylacetone.

(B) Some of these substances may be known by trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.

(vi) Nabilone, another name for nabilone:

(±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one.

(c) Schedule III:

(i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(A) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;

(B) Benzphetamine;

(C) Chlorphentermine;

(D) Clortermine; and

(E) Phendimetrazine.

(ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which are not listed in any schedule;

## HB0110S01 compared with HB0110

(B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug Administration for marketing only as a suppository;

(C) Any substance which contains any quantity of a derivative of barbituric acid or any salt of any of them;

(D) Chlorhexadol;

(E) Buprenorphine;

(F) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under the federal Food, Drug, and Cosmetic Act, Section 505;

(G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:  $\pm$  -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

(H) Lysergic acid;

(I) Lysergic acid amide;

(J) Methyprylon;

(K) Sulfondiethylmethane;

(L) Sulfonethylmethane;

(M) Sulfonmethane; and

(N) Tiletamine and zolazepam or any of their salts, some trade or other names for a tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon.

(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product, some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol.

(iv) Nalorphine.

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:

## **HB0110S01 compared with HB0110**

(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;

(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;

(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and

(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth:

- (A) Boldenone;
- (B) Chlorotestosterone (4-chlortestosterone);
- (C) Clostebol;
- (D) Dehydrochlormethyltestosterone;
- (E) Dihydrotestosterone (4-dihydrotestosterone);

## HB0110S01 compared with HB0110

- (F) Drostanolone;
- (G) Ethylestrenol;
- (H) Fluoxymesterone;
- (I) Formebolone (formebolone);
- (J) Mesterolone;
- (K) Methandienone;
- (L) Methandranone;
- (M) Methandriol;
- (N) Methandrostenolone;
- (O) Methenolone;
- (P) Methyltestosterone;
- (Q) Mibolerone;
- (R) Nandrolone;
- (S) Norethandrolone;
- (T) Oxandrolone;
- (U) Oxymesterone;
- (V) Oxymetholone;
- (W) Stanolone;
- (X) Stanozolol;
- (Y) Testolactone;
- (Z) Testosterone; and
- (AA) Trenbolone.

(vii) Anabolic steroids expressly intended for administration through implants to cattle or other nonhuman species, and approved by the Secretary of Health and Human Services for use, may not be classified as a controlled substance.

(d) Schedule IV:

(i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.

(ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances,

## HB0110S01 compared with HB0110

including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (A) Alprazolam;
- (B) Barbitol;
- (C) Bromazepam;
- (D) Butorphanol;
- (E) Camazepam;
- (F) Carisoprodol;
- (G) Chloral betaine;
- (H) Chloral hydrate;
- (I) Chlordiazepoxide;
- (J) Clobazam;
- (K) Clonazepam;
- (L) Clorazepate;
- (M) Clotiazepam;
- (N) Cloxazolam;
- (O) Delorazepam;
- (P) Diazepam;
- (Q) Dichloralphenazone;
- (R) Estazolam;
- (S) Ethchlorvynol;
- (T) Ethinamate;
- (U) Ethyl loflazepate;
- (V) Fludiazepam;
- (W) Flunitrazepam;
- (X) Flurazepam;
- (Y) Halazepam;
- (Z) Haloxazolam;
- (AA) Ketazolam;
- (BB) Loprazolam;
- (CC) Lorazepam;



## HB0110S01 compared with HB0110

(DD) Lormetazepam;  
(EE) Mebutamate;  
(FF) Medazepam;  
(GG) Meprobamate;  
(HH) Methohexital;  
(II) Methylphenobarbital (mephobarbital);  
(JJ) Midazolam;  
(KK) Nimetazepam;  
(LL) Nitrazepam;  
(MM) Nordiazepam;  
(NN) Oxazepam;  
(OO) Oxazolam;  
(PP) Paraldehyde;  
(QQ) Pentazocine;  
(RR) Petrichloral;  
(SS) Phenobarbital;  
(TT) Pinazepam;  
(UU) Prazepam;  
(VV) Quazepam;  
(WW) Temazepam;  
(XX) Tetrazepam;  
(YY) Triazolam;  
(ZZ) Zaleplon; and  
(AAA) Zolpidem.

(iii) Any material, compound, mixture, or preparation of fenfluramine which contains any quantity of the following substances, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible.

(iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether

## HB0110S01 compared with HB0110

optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (A) Cathine ((+)-norpseudoephedrine);
- (B) Diethylpropion;
- (C) Fencamfamine;
- (D) Fenproporex;
- (E) Mazindol;
- (F) Mefenorex;
- (G) Modafinil;
- (H) Pemoline, including organometallic complexes and chelates thereof;
- (I) Phentermine;
- (J) Pipradrol;
- (K) Sibutramine; and
- (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

(e) Schedule V: Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

- (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
- (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
- (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
- (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
- (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
- (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of

## HB0110S01 compared with HB0110

atropine sulfate per dosage unit;

(vii) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers; and

(viii) all forms of Tramadol.

Section 2. Section 58-37-4.2 is amended to read:

### 58-37-4.2. Listed controlled substances.

The following substances, their analogs, homologs, and synthetic equivalents are listed controlled substances:

(1) AB-001;

(2) AB-PINACA;

N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;

(3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide;

(4) ADB-CHMINACA: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide;

(5) ADB-FUBINACA: (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide);

[(4)] (6) AKB48;

[(5)] (7) alpha-Pyrrolidinovalerophenone (alpha-PVP);

[(6)] (8) AM-694; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;

[(7)] (9) AM-1248;

[(8)] (10) AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;

[(9)] (11) AM-2233;

[(10)] (12) AM-679;

[(11)] (13) A796,260;

[(12)] (14) Butylone;

[(13)] (15) CP 47,497 and its C6, C8, and C9 homologs;

2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol;

[(14)] (16) Diisopropyltryptamine (DiPT);

[(15)] (17) Ethylone;

## HB0110S01 compared with HB0110

[(16)] (18) Ethylphenidate;

[(17)] (19) Fluoroisocathinone;

[(18)] (20) Fluoromethamphetamine;

[(19)] (21) Fluoromethcathinone;

(22) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;

[(20)] (23) HU-210;

(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)

-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

[(21)] (24) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

[(22)] (25) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;

[(23)] (26) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as 1-Pentyl-3-(1-naphthoyl)indole};

[(24)] (27) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;

[(25)] (28) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as 1-Butyl-3-(1-naphthoyl)indole};

[(26)] (29) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;

[(27)] (30) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);

[(28)] (31) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;

[(29)] (32) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;

[(30)] (33) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;

[(31)] (34) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;

[(32)] (35) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;

[(33)] (36) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;

[(34)] (37) MAM-2201;

[(35)] (38) MAM-2201;

(1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;

[(36)] (39) Methoxetamine;

[(37)] (40) Naphyrone;

[(38)] (41) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;

[(39)] (42) Pentedrone;

## HB0110S01 compared with HB0110

[(40)] (43) Pentylone;

[(41)] (44) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;

[(42)] (45) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as BTW-8 and SR-18};

[(43)] (46) STS-135;

[(44)] (47) UR-144;

[(45)] (48) UR-144 N-(5-chloropentyl) analog;

[(46)] (49) XLR11;

[(47)] (50) 2C-C;

[(48)] (51) 2C-D;

[(49)] (52) 2C-E;

[(50)] (53) 2C-H;

[(51)] (54) 2C-I;

[(52)] (55) 2C-N;

[(53)] (56) 2C-P;

[(54)] (57) 2C-T-2;

[(55)] (58) 2C-T-4;

[(56)] (59) 2NE1;

[(57)] (60) 25I-NBOMe;

[(58)] (61) 2,5-Dimethoxy-4-chloroamphetamine (DOC);

[(59)] (62) 4-methylmethcathinone {also known as mephedrone};

[(60)] (63) 3,4-methylenedioxypropylvalerone {also known as MDPV};

[(61)] (64) 3,4-Methylenedioxymethcathinone {also known as methylone};

[(62)] (65) 4-methoxymethcathinone;

[(63)] (66) 4-Methyl-alpha-pyrrolidinopropiophenone;

[(64)] (67) 4-Methylethcathinone;

[(65)] (68) 5F-AKB48;

1-(5-fluoropentyl)-N-tricyclo[3.3.1.1.3,7]dec-1-yl-1H-indazole-3-carboxamide;

[(66)] (69) 5-fluoro-PB-22; 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester;

[(67)] (70) 5-Iodo-2-aminoindane (5-IAI);

## HB0110S01 compared with HB0110

~~[(68)]~~ (71) 5-MeO-DALT;

~~[(69)]~~ (72) 25B-NBOMe; 2-(~~r~~-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;

~~[(70)]~~ (73) 25C-NBOMe; 2-(4Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; and

~~[(71)]~~ (74) 25H-NBOMe;  
2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.

Section ~~{2}~~3. **Effective date.**

If approved by two-thirds of all the members elected to each house, this bill takes effect upon approval by the governor, or the day following the constitutional time limit of Utah Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto, the date of veto override.

†

**Legislative Review Note**

**Office of Legislative Research and General Counsel†**